Маркетинговий аналіз сегмента ринку лікарських засобів – похідних 9,10-антрахінону в УкраїнІ

dc.citation.epage125
dc.citation.issue1
dc.citation.spage116
dc.contributor.affiliationНаціональний університет “Львівська політехніка”
dc.contributor.affiliationLviv Polytechnic National University
dc.contributor.authorСтасевич, М. В.
dc.contributor.authorЗварич, В. І.
dc.contributor.authorStasevych, M. V.
dc.contributor.authorZvarych, V. I.
dc.coverage.placenameЛьвів
dc.coverage.placenameLviv
dc.date.accessioned2024-01-22T08:14:43Z
dc.date.available2024-01-22T08:14:43Z
dc.date.created2021-03-16
dc.date.issued2021-03-16
dc.description.abstractПроведено маркетинговий аналіз фармацевтичного ринку лікарських засобів – похідних 9,10-антрахінону. Показано, що на ринку України асортимент цих препаратів сформований переважно лікарськими засобами закордонного виробництва, лідерами якого є країнивиробники Австрія, Італія, Німеччина та Індія. Визначено, що більшість антрахінонвмісних лікарських препаратів представлена засобами для лікування онкологічних захворювань різних типів та посилення перистальтики кишечника. Встановлено, що в Україні виробництвом трьох протипухлинних субстанцій займається ТОВ “Сінбіас Фарма”. Вітчизняними виробниками препаратів на основі антрахінонвмісної лікарської рослинної сировини є ПрАТ “Ліктрави” та ПрАТ Фармацевтична фабрика “Віола”, а виробниками глікозидів сени – АТ “Лубнифарм”, ТОВ “Тернофарм” та Фармацевтична компанія “Здоров’я”. Основними лікарськими формами лікарських засобів – похідних 9,10-антрахінону є ін’єкційні розчини, ліофілізати, таблетки та капсули тверді.
dc.description.abstractA marketing analysis of the pharmaceutical market for drugs - derivatives of 9,10-anthraquinone was carried out. It is shown that in the Ukrainian market, the vast majority of the assortment of these drugs is formed by foreign-made drugs, the leaders of which are the manufacturing countries Austria, Italy, Germany and India. It has been determi ned that the majority of anthraquinone drugs are represented by agents for the treatment of diseases of varioustypes of cancer and strengthening ofthe intestinal reticulum.It has been established that “Sinbias Pharma” LLC is engaged in the production of four anticancer substances in Ukraine. For preparations based on anthraquinone-containing medicinal herbal raw materials, domestic manufacturers are PJSC “Liktravy” and PJSC Pharmaceutical Factory “Viola”, and the producers of senna glycosides are JSC “Lubnypharm”, “Ternopharm” LLC and Pharmaceutical company “Zdorovye”. Injection solutions, lyophilisates, tablets and hard capsules are the main dosage forms of drugs – derivatives of 9,10-anthraquinone.
dc.format.extent116-125
dc.format.pages10
dc.identifier.citationСтасевич М. В. Маркетинговий аналіз сегмента ринку лікарських засобів – похідних 9,10-антрахінону в УкраїнІ / М. В. Стасевич, В. І. Зварич // Chemistry, Technology and Application of Substances. — Львів : Видавництво Львівської політехніки, 2021. — Том 4. — № 1. — С. 116–125.
dc.identifier.citationenStasevych M. V. Marketing analysis of the market segment of drugs – derivatives of 9,10-anthraquinone in Ukraine / M. V. Stasevych, V. I. Zvarych // Chemistry, Technology and Application of Substances. — Lviv : Lviv Politechnic Publishing House, 2021. — Vol 4. — No 1. — P. 116–125.
dc.identifier.doidoi.org/10.23939/ctas2021.01.116
dc.identifier.urihttps://ena.lpnu.ua/handle/ntb/60846
dc.language.isouk
dc.publisherВидавництво Львівської політехніки
dc.publisherLviv Politechnic Publishing House
dc.relation.ispartofChemistry, Technology and Application of Substances, 1 (4), 2021
dc.relation.references1. Fouillaud, M., Venkatachalam, M., GirardValenciennes, E., Caro, Y., Dufossé, L.(2016). Anthraquinones and derivatives from marine-derived fungi: Structural Diversity and Selected Biological Activities. Marine Drugs, 14(4), 64. doi:10.3390/md14040064. Retrieved from https://www.mdpi.com/1660-3397/14/4/64
dc.relation.references2. Fouillaud, M., Caro, Y., Venkatachalam, M., Grondin, I., & Dufossé L. (2018). Anthraquinones. In: L. M. L. Nollet; J. A. Gutiérrez-Uribe (eds). Phenolic Compounds in Food Characterization and Analysis, 130–170. CRC Press.
dc.relation.references3. Malik, E. M. & Müller, C. E. (2016). Anthraquinones As Pharmacological Tools and Drugs. Medicinal Research Reviews, 36, 705–748. doi:10.1002/med.21391
dc.relation.references4. Hussain, H., Al-Harrasi, A., Al-Rawahi, A., Green, I. R., Csuk, R., Ahmed, I., Shah, A., Abbas, G., Rehman, N. U. & Ullah, R. (2015). A fruitful decade from 2005 to 2014 for anthraquinone patents, Expert Opinion on Therapeutic Patents, 25(9), 1053–1064. doi:10.1517/13543776.2015.1050793
dc.relation.references5. Tikhomirov, A. S., Shtil, A. A., Shchekotikhin, A. E. (2018). Advances in the Discovery of Anthraquinone-Based Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 13(2), 159–183. doi:10.2174/1574892813666171206123114.
dc.relation.references6. Siddamurthi, S., Gutti, G., Jana, S., Kumar, A., & Singh S. K. (2020). Anthraquinone: a promising scaffold for the discovery and development of therapeutic agents in cancer therapy. Future Medicinal Chemistry, 12(11), 1037–1069. doi:10.4155/fmc-2019-0198.
dc.relation.references7. Zvarich, V. I., Stasevich, M. V.; Stan’ko, O. V.; Komarovskaya-Porokhnyavets, E. Z.; Poroikov, V. V.; Rudik, A. V.; Lagunin, A. A.; Vovk, M. V.; & Novikov, V. P. (2014). Computerized prediction, synthesis, and antimicrobial activity of new amino-acid derivatives of 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide. Pharmaceutical Chemistry Journal, 48, 584–588. doi: 10.1007/s11094-014-1154-z.
dc.relation.references8. Zvarych, V., Stasevych, M., Novikov, V., & Vovk, M. (2021). Synthesis and Study of Antimicrobial Activity of 2-Dithiocarbamate-N-(9,10-Dioxo-9,10-Dihydroanthraceny l)Acetamides, Biointerface Research in Applied Chemistry, 11(1), 7725–7734. doi: 10.33263/BRIAC111.77257734
dc.relation.references9. Zvarych, V., Stasevych, M., Novikov, V., Rusanov, E., Vovk, M., Szweda, P., Grecka, K., & Milewski, S. (2019). Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a new class of antistaphylococcal agents: synthesis and biological evaluation. Molecules, 24, 4581. doi:10.3390/molecules24244581. Retrieved from https://www.mdpi.com/1420-3049/24/24/4581
dc.relation.references10. Halenova, T.I., Nikolaeva,I. V., Stasevych,M. V., Zvarych, V. I., Lunin, V. V., Novikov, V. P., & Savchuk, O. M. (2017). Platelet aggregation under the influence of some dithiocarbamate derivatives of 9,10-anthracenedione. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 8, 1626–1632. Retrieved from https://www.rjpbcs.com/pdf/2017_8(1)/[203].pdf
dc.relation.references11. Stasevych, M. V., Zvarych, V. I., Spreis, D. R., & Yaremkevych, O. S. (2019). Computer prediction and verification of antioxidative activity of exo-functionalized derivatives of 9,10-antraquinone. Chemistry, Technology and Application of Substances, 2(1), 83–91. doi:10.23939/ctas2019.01.083
dc.relation.references12. Thomson Reuters Integrity database. Retrieved from http:// https://integrity.clarivate.com/integrity/xmlxsl/ (accessed December 14, 2019)
dc.relation.references13. Derzhavnyi reiestr likarskykh zasobiv Ukrainy, (2020). Retrieved from http://www.drlz.com.ua (in Ukrainian)
dc.relation.references14. A searchable version of the complete ATC index with DDDs “ATC/DDD Index 2021”. (2021). Retrieved from https://www.whocc.no/atc_ddd_index/
dc.relation.references15. Spetsializovane medychne internet-vydannia dlia likariv, provizoriv, farmatsevtiv, studentiv medychnykh i farmatsevtychnykh vuziv “Kompendium Online”, (2021). Retrieved from https://compendium.com.ua (in Ukrainian)
dc.relation.references16. Servis “Liki control” (2021). Retrieved from http://likicontrol.com.ua. [in Ukrainian]
dc.relation.references17. Online database “DrugBank Online” (2021). Retrieved from https://www.drugbank.com
dc.relation.references18. Online database “Drugs.com” (2021). Retrieved from https://www.drugs.com
dc.relation.references19. Halterman, P., Vogelzang, N.J., Farabishahadel, A., & Goodman O.B. (2010). Mitoxantrone. In: Figg W., Chau C., Small E. (eds) Drug Management of Prostate Cancer. New York: Springer.
dc.relation.references20. Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E.,. Reginster, J. Y. (2016). Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs & aging, 33(2), 75–85. doi: 10.1007/s40266-016-0347-4
dc.relation.references21. Report on Carcinogens, Fourteenth Edition (2016, November 3). Danthron. Retrieved from https://ntp.niehs.nih.gov/ntp/roc/content/profiles/danthron.pdf
dc.relation.references22. Lichtman M. A. (2013). A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells, Molecules and Diseases, 50(2), 119–130. doi:10.1016/j.bcmd.2012.10.005
dc.relation.references23. Manufacturing Issues Remain for Indevus’ Valstar (2008, January 11). Retrieved from https://www.fdanews.com/articles/103010-manufacturing-issues-remain-forindevus-valstar Diaz-Muñoz, G., Miranda, I. L., Sartori, S. K., de Rezende, D. C., & Diaz, M. A. N. (2018). Chapter 11 – Anthraquinones: An Overview. Studies in Natural Products Chemistry, 58, 313–338. doi:10.1016/B978-0-444-64056-7.00011-8
dc.relation.references24. Koval’ov, V. M., Pavlin, O. I., & Isakova, T. I. (2004). Farmakohnoziya z osnovamy biokhimiyi roslyn. Vyd-vo NFaU MTK-knyha, Kharkiv.
dc.relation.references25. Sait „Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny” (2021). Baytach. Retrieved from https://mozdocs.kiev.ua/likiview.php?id=28047
dc.relation.references26. Sait „Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny” (2021). PYRALVEX Retrieved from https://mozdocs.kiev.ua/likiview.php?id=3333
dc.relation.referencesen1. Fouillaud, M., Venkatachalam, M., GirardValenciennes, E., Caro, Y., Dufossé, L.(2016). Anthraquinones and derivatives from marine-derived fungi: Structural Diversity and Selected Biological Activities. Marine Drugs, 14(4), 64. doi:10.3390/md14040064. Retrieved from https://www.mdpi.com/1660-3397/14/4/64
dc.relation.referencesen2. Fouillaud, M., Caro, Y., Venkatachalam, M., Grondin, I., & Dufossé L. (2018). Anthraquinones. In: L. M. L. Nollet; J. A. Gutiérrez-Uribe (eds). Phenolic Compounds in Food Characterization and Analysis, 130–170. CRC Press.
dc.relation.referencesen3. Malik, E. M. & Müller, C. E. (2016). Anthraquinones As Pharmacological Tools and Drugs. Medicinal Research Reviews, 36, 705–748. doi:10.1002/med.21391
dc.relation.referencesen4. Hussain, H., Al-Harrasi, A., Al-Rawahi, A., Green, I. R., Csuk, R., Ahmed, I., Shah, A., Abbas, G., Rehman, N. U. & Ullah, R. (2015). A fruitful decade from 2005 to 2014 for anthraquinone patents, Expert Opinion on Therapeutic Patents, 25(9), 1053–1064. doi:10.1517/13543776.2015.1050793
dc.relation.referencesen5. Tikhomirov, A. S., Shtil, A. A., Shchekotikhin, A. E. (2018). Advances in the Discovery of Anthraquinone-Based Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 13(2), 159–183. doi:10.2174/1574892813666171206123114.
dc.relation.referencesen6. Siddamurthi, S., Gutti, G., Jana, S., Kumar, A., & Singh S. K. (2020). Anthraquinone: a promising scaffold for the discovery and development of therapeutic agents in cancer therapy. Future Medicinal Chemistry, 12(11), 1037–1069. doi:10.4155/fmc-2019-0198.
dc.relation.referencesen7. Zvarich, V. I., Stasevich, M. V.; Stan’ko, O. V.; Komarovskaya-Porokhnyavets, E. Z.; Poroikov, V. V.; Rudik, A. V.; Lagunin, A. A.; Vovk, M. V.; & Novikov, V. P. (2014). Computerized prediction, synthesis, and antimicrobial activity of new amino-acid derivatives of 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide. Pharmaceutical Chemistry Journal, 48, 584–588. doi: 10.1007/s11094-014-1154-z.
dc.relation.referencesen8. Zvarych, V., Stasevych, M., Novikov, V., & Vovk, M. (2021). Synthesis and Study of Antimicrobial Activity of 2-Dithiocarbamate-N-(9,10-Dioxo-9,10-Dihydroanthraceny l)Acetamides, Biointerface Research in Applied Chemistry, 11(1), 7725–7734. doi: 10.33263/BRIAC111.77257734
dc.relation.referencesen9. Zvarych, V., Stasevych, M., Novikov, V., Rusanov, E., Vovk, M., Szweda, P., Grecka, K., & Milewski, S. (2019). Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a new class of antistaphylococcal agents: synthesis and biological evaluation. Molecules, 24, 4581. doi:10.3390/molecules24244581. Retrieved from https://www.mdpi.com/1420-3049/24/24/4581
dc.relation.referencesen10. Halenova, T.I., Nikolaeva,I. V., Stasevych,M. V., Zvarych, V. I., Lunin, V. V., Novikov, V. P., & Savchuk, O. M. (2017). Platelet aggregation under the influence of some dithiocarbamate derivatives of 9,10-anthracenedione. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 8, 1626–1632. Retrieved from https://www.rjpbcs.com/pdf/2017_8(1)/[203].pdf
dc.relation.referencesen11. Stasevych, M. V., Zvarych, V. I., Spreis, D. R., & Yaremkevych, O. S. (2019). Computer prediction and verification of antioxidative activity of exo-functionalized derivatives of 9,10-antraquinone. Chemistry, Technology and Application of Substances, 2(1), 83–91. doi:10.23939/ctas2019.01.083
dc.relation.referencesen12. Thomson Reuters Integrity database. Retrieved from http:// https://integrity.clarivate.com/integrity/xmlxsl/ (accessed December 14, 2019)
dc.relation.referencesen13. Derzhavnyi reiestr likarskykh zasobiv Ukrainy, (2020). Retrieved from http://www.drlz.com.ua (in Ukrainian)
dc.relation.referencesen14. A searchable version of the complete ATC index with DDDs "ATC/DDD Index 2021". (2021). Retrieved from https://www.whocc.no/atc_ddd_index/
dc.relation.referencesen15. Spetsializovane medychne internet-vydannia dlia likariv, provizoriv, farmatsevtiv, studentiv medychnykh i farmatsevtychnykh vuziv "Kompendium Online", (2021). Retrieved from https://compendium.com.ua (in Ukrainian)
dc.relation.referencesen16. Servis "Liki control" (2021). Retrieved from http://likicontrol.com.ua. [in Ukrainian]
dc.relation.referencesen17. Online database "DrugBank Online" (2021). Retrieved from https://www.drugbank.com
dc.relation.referencesen18. Online database "Drugs.com" (2021). Retrieved from https://www.drugs.com
dc.relation.referencesen19. Halterman, P., Vogelzang, N.J., Farabishahadel, A., & Goodman O.B. (2010). Mitoxantrone. In: Figg W., Chau C., Small E. (eds) Drug Management of Prostate Cancer. New York: Springer.
dc.relation.referencesen20. Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E.,. Reginster, J. Y. (2016). Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs & aging, 33(2), 75–85. doi: 10.1007/s40266-016-0347-4
dc.relation.referencesen21. Report on Carcinogens, Fourteenth Edition (2016, November 3). Danthron. Retrieved from https://ntp.niehs.nih.gov/ntp/roc/content/profiles/danthron.pdf
dc.relation.referencesen22. Lichtman M. A. (2013). A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells, Molecules and Diseases, 50(2), 119–130. doi:10.1016/j.bcmd.2012.10.005
dc.relation.referencesen23. Manufacturing Issues Remain for Indevus’ Valstar (2008, January 11). Retrieved from https://www.fdanews.com/articles/103010-manufacturing-issues-remain-forindevus-valstar Diaz-Muñoz, G., Miranda, I. L., Sartori, S. K., de Rezende, D. C., & Diaz, M. A. N. (2018). Chapter 11 – Anthraquinones: An Overview. Studies in Natural Products Chemistry, 58, 313–338. doi:10.1016/B978-0-444-64056-7.00011-8
dc.relation.referencesen24. Koval’ov, V. M., Pavlin, O. I., & Isakova, T. I. (2004). Farmakohnoziya z osnovamy biokhimiyi roslyn. Vyd-vo NFaU MTK-knyha, Kharkiv.
dc.relation.referencesen25. Sait "Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny" (2021). Baytach. Retrieved from https://mozdocs.kiev.ua/likiview.php?id=28047
dc.relation.referencesen26. Sait "Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny" (2021). PYRALVEX Retrieved from https://mozdocs.kiev.ua/likiview.php?id=3333
dc.relation.urihttps://www.mdpi.com/1660-3397/14/4/64
dc.relation.urihttps://www.mdpi.com/1420-3049/24/24/4581
dc.relation.urihttps://www.rjpbcs.com/pdf/2017_8(1)/
dc.relation.urihttps://integrity.clarivate.com/integrity/xmlxsl/
dc.relation.urihttp://www.drlz.com.ua
dc.relation.urihttps://www.whocc.no/atc_ddd_index/
dc.relation.urihttps://compendium.com.ua
dc.relation.urihttp://likicontrol.com.ua
dc.relation.urihttps://www.drugbank.com
dc.relation.urihttps://www.drugs.com
dc.relation.urihttps://ntp.niehs.nih.gov/ntp/roc/content/profiles/danthron.pdf
dc.relation.urihttps://www.fdanews.com/articles/103010-manufacturing-issues-remain-forindevus-valstar
dc.relation.urihttps://mozdocs.kiev.ua/likiview.php?id=28047
dc.relation.urihttps://mozdocs.kiev.ua/likiview.php?id=3333
dc.rights.holder© Національний університет “Львівська політехніка”, 2021
dc.subject9
dc.subject10-антрахінон
dc.subjectактивний фармацевтичний інгредієнт
dc.subjectлікарський препарат
dc.subjectаналіз ринку лікарських препаратів на основі похідних 9
dc.subject10-антрахінону
dc.subjectасортимент лікарських засобів
dc.subjectлікарська форма
dc.subjectлікарська рослинна сировина
dc.subjectгомеопатичні препарати
dc.subject: 9
dc.subject10-anthraquinone
dc.subjectactive pharmaceutical ingredient
dc.subjectmedicinal product
dc.subjectmarket analysis of drugs based on derivatives of 9
dc.subject10-anthraquinone
dc.subjectrange of drugs
dc.subjectdosage form
dc.subjectherbal raw materials
dc.subjecthomeopathic preparations
dc.titleМаркетинговий аналіз сегмента ринку лікарських засобів – похідних 9,10-антрахінону в УкраїнІ
dc.title.alternativeMarketing analysis of the market segment of drugs – derivatives of 9,10-anthraquinone in Ukraine
dc.typeArticle

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
2021v4n1_Stasevych_M_V-Marketing_analysis_116-125.pdf
Size:
1.08 MB
Format:
Adobe Portable Document Format
Thumbnail Image
Name:
2021v4n1_Stasevych_M_V-Marketing_analysis_116-125__COVER.png
Size:
436.04 KB
Format:
Portable Network Graphics

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.8 KB
Format:
Plain Text
Description: